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1. Data {#sec1}
=======

We investigated the effect on urine assays of hydroxychloroquine at concentration up to 1000 mg/L spiked into pools of de-identified urine specimens from the university medical center central clinical laboratory. This followed from observation that a patient with a large overdose of hydroxychloroquine showed suspected interference for some urine laboratory tests obtained for clinical care \[[@bib1]\]. There is limited published data that hydroxychloroquine can interfere with urine protein dipstick methods \[[@bib2],[@bib3]\] and with some urine drug screening tests \[[@bib4]\]. A detailed review of package inserts for drug of abuse and therapeutic drug monitoring assays did not find hydroxychloroquine reported as an interferent in any of the assays \[[@bib5],[@bib6]\].

The 24 specific urine assays analyzed are as follows: amphetamines drug screen, amylase, benzodiazepines drug screen, buprenorphine drug screen, calcium, chloride, cocaine metabolite screen, cotinine screen, creatinine, glucose, human chorionic gonadotropin (hCG), magnesium, microalbumin, myoglobin, NGAL, opiates drug screen, oxycodone drug screen, pH, phosphorus, potassium, protein, sodium, tetrahydrocannabinol (THC) drugs screen, and urea nitrogen. Technical details on these 24 urine assays are available elsewhere \[[@bib1]\]. The assays were initially screened in triplicate for a single de-identified pooled urine sample. Thirteen of the assays showed no absorbance or other alarms/errors and also did not have any results that differed by more than 15% from the control without hydroxychloroquine. The raw data for these 13 assays is in [Table 1](#tbl1){ref-type="table"}. Raw data for the remaining 11 assays is in [Table 2](#tbl2){ref-type="table"}. These were all tested in triplicate for a total of 4 separate pooled urine samples.Table 1Raw data for 13 urine assays on a single pooled urine samples.Table 1AssayUnitsHydroxychoroquine concentration0 mg/L1 mg/L10 mg/L100 mg/L500 mg/L1000 mg/LAmylaseU/L121121123122121122Calciummg/dL10.410.410.610.89.910.0Chloridemmol/L69.070.768.070.372.776.7Creatininemg/dL76.979.379.377.882.380.7Glucosemg/dL6.05.55.45.36.06.0hCGmIU/mL1.01.11.11.11.01.1Magnesiummg/dL4.84.74.74.74.34.2NGALng/mL12.011.011.512.011.011.5pHpH units76.86.96.96.96.9Phosphorusmg/dL20.421.322.021.619.620.1Potassiummmol/L353534353939Proteinmg/dL555757585449Sodiummmol/L606261626566Table 2Raw data for 13 urine assays on four separate pooled urine samples.Table 2AssayUnitsSample \#Hydroxychloroquine concentration0 mg/L1 mg/L10 mg/L100 mg/L500 mg/L1000 mg/LAmphetamines Drug ScreenRelative1−268−286−276−281−271−250absorbance units2−302−323−309−314−298−291(positive: \>0)3−273−283−284−279−281−2644−299−299−295−298−283−265Benzodiazepines Drug ScreenRelative1−187−178−176−174−171−164absorbance units2−263−204−209−201−185−58(positive: \>0)3−210−181−183−176−176−1724102108106105105107Buprenorphine Drug ScreenRelative1−339−441−441−472−534Absorbance errorabsorbance units2−283−421−410−429−472Absorbance error(positive: \>0)3−283−393−398−420−418Absorbance error4−258−389−395−405−451Absorbance errorCocaine Drug ScreenRelative1−548−538−554−557−565−540absorbance units2−575−587−570−581−578−558(positive: \>0)3−553−543−546−546−537−5364−558−560−568−570−551−552Cotinine ScreenRelative1\>2000\>2000\>2000\>2000\>2000Absorbance errorabsorbance units21294786810784705Absorbance error(positive: \>0)3−250−194−182−202−268Absorbance error4229398397348119Absorbance errorMicroalbuminmcg/mg creatinine1293273273281315329215510510511214418932420232426304215225224231249274Myoglobinng/mL1\<21\<21\<21\<21\<21\<21210088999008767525993\<21\<21\<21\<21\<21\<214\<21\<21\<21\<21\<21\<21Opiates Drug ScreenRelative1881031011019689absorbance units2−520−497−496−496−469−436(positive: \>0)3−483−477−455−475−458−4594−479−446−453−447−426−392Oxycodone Drug ScreenRelative1−158−159−160−158−158Absorbance errorabsorbance units22831323127Absorbance error(positive: \>0)3−154−159−159−157−156Absorbance error4−155−155−156−155−153Absorbance errorUrea nitrogenmg/dL1859862884877866863268469669269467364739519279309269309234541529531519519518THC Drug ScreenRelative1−178−165−162−163−155−126absorbance units2−221−191−186−180−167−152(positive: \>0)3−225−206−206−207−195−2014−225−210−211−212−194−180

[Fig. 1](#fig1){ref-type="fig"} shows data for 4 of the assays (amphetamine screen, benzodiazepine screen, buprenorphine screen, and cocaine screen). An absorbance alarm was evident for all 4 samples containing 1000 mg/L hydroxychloroquine for the buprenorphine screen ([Fig. 1](#fig1){ref-type="fig"}B). [Fig. 2](#fig2){ref-type="fig"} shows data for another 4 of the assays (cotinine screen, microalbumin, myoglobin, and opiates screen). Positive bias and absorbance errors were evident for the cotinine assay for all 4 specimens ([Fig. 2](#fig2){ref-type="fig"}A). Biphasic effects of hydroxychloroquine were evident for the microalbumin assay, especially for samples 1, 2, and 4 ([Fig. 2](#fig2){ref-type="fig"}B). A negative bias was evident for the myoglobin assay for sample 2 ([Fig. 2](#fig2){ref-type="fig"}C). The remaining urine samples had \<21 ng/mL myoglobin and did not show any evident effect of hydroxychloroquine, although a negative bias would not be detectable in these 3 samples with the myoglobin concentrations below the lower limit of quantitation. [Fig. 3](#fig3){ref-type="fig"} shows data for the remaining 3 assays analyzed in detail. Absorbance errors were evident for the oxycodone for all 4 samples spiked with 1000 mg/L ([Fig. 3](#fig3){ref-type="fig"}A). A positive bias from hydroxychloroquine was evident for all 4 samples analyzed for tetrahydrocannabinol (THC; [Fig. 3](#fig3){ref-type="fig"}B), although all 4 of these samples would still be negative in this qualitative assay.Fig. 1Analysis of hydroxychloroquine effects on urine assays for (A) amphetamine screen, (B) benzodiazepine screen, (C) buprenorphine screen, and (D) cocaine screen. Four separate de-identified pooled urine samples were tested in triplicate at the indicated hydroxychloroquine concentrations.Fig. 1Fig. 2Analysis of hydroxychloroquine effects on urine assays for (A) cotinine screen, (B) microalbumin screen, (C) myoglobin assay, and (D) opiates screen. Four separate de-identified pooled urine samples were tested in triplicate at the indicated hydroxychloroquine concentrations.Fig. 2Fig. 3Analysis of hydroxychloroquine effects on urine assays for (A) oxycodone screen, (B) tetahydrocannabinol (THC) screen, and (C) urea nitrogen. Four separate de-identified pooled urine samples were tested in triplicate at the indicated hydroxychloroquine concentrations.Fig. 3

2. Experimental design, materials, and methods {#sec2}
==============================================

All analyses were performed on Roche Diagnostics cobas 8000 analyzers (c501, c502, c602, and c701). The complete list of assays with vendor name, methodology, and assay version are summarized elsewhere \[[@bib1]\]. All assays were run in accordance with package insert instructions. A total of 4 pooled urine specimens were prepared using de-identified specimens from the clinical laboratory. All 24 assays were tested in triplicate for 1 of the urine pools. As described above, 11 of the assays were then tested and triplicate for the remaining 3 urine pools. The raw data consists of concentration or absorbance units for the specimens. It should be noted that the urine total protein method used for the data in this report uses a biuret complex method using divalent copper in alikaline solution \[[@bib7]\]. This is in contrast to previous studies using tetrabromophenol blue \[[@bib3]\] and pyrogallol red-molybdate methods \[[@bib2]\] that showed interference by hydroxychloroquine.
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